ScaleReady and Germfree discuss the need to rethink sustainability and move towards a more standardized and simplistic manufacturing model to ensure health equity can be achieved. This episode of our monthly podcast Voices of Biotech brings you an interesting conversation with Carol Houts, chief strategy officer at Germfree and Josh Ludwig, global director commercial operations at ScaleReady. Together, they discuss how sustainability measures can increase patient care and access through decentralized manufacturing models, which can reduce the time, space, and cost associated with producing cell and gene therapies (CGTs) and other modalities. The conversation about sustainability leads into a discussion about the ecosystem in the life sciences space. While both acknowledged and spoke in-depth about the advantages of educating the industry and shifting towards a more decentralized manufacturing model, Ludwig and Houts did not shy away from discussing some of the challenges the industry faces. These include the shortage of talent in the space, the element of many players still “figuring it out” as sustainability is not an individual issue but a collective one, and the issue of drug shortages. The pair ended the podcast with some thought-provoking statements regarding the need to rethink what sustainability means and urged how standardization is really the key to achieving better patient care and access. The latest episode can be found here or through the BioProcess Insider Expression Platform at, Spotify, Apple iTunes, Google podcasts, or wherever you get your podcasts.